Core Insights - CervoMed Inc. has appointed Matthew Winton, Ph.D., as Chief Commercial and Business Officer to enhance its executive leadership team as it prepares for late-stage development and market readiness [1][2] - Dr. Winton brings nearly two decades of experience in the biotechnology industry, with a focus on commercializing treatments in the central nervous system (CNS) space [1][2] Company Developments - The appointment of Dr. Winton is seen as pivotal as CervoMed advances into late-stage Phase 3 development of neflamapimod, aimed at treating dementia with Lewy bodies (DLB) [2] - Dr. Winton's previous roles include Chief Operating Officer at Inozyme Pharma and senior leadership positions at Biogen, where he managed multi-billion-dollar neurology portfolios [2][3] Product Focus - CervoMed is developing neflamapimod, an investigational orally administered small molecule that targets synaptic dysfunction associated with neurodegenerative diseases like DLB [5] - The company recently completed a Phase 2b trial for neflamapimod, indicating progress in its clinical development [5] Inducement Grants - On October 6, 2025, CervoMed granted Dr. Winton an option to purchase 75,000 shares of common stock at an exercise price of $8.62, with vesting over three years [4]

Core Insights - CervoMed Inc. is participating in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, in New York, NY [1][2] - The company is focused on developing treatments for age-related neurologic disorders, specifically through its investigational drug neflamapimod [3] Company Overview - CervoMed is a clinical-stage company targeting age-related neurologic disorders [3] - The company is developing neflamapimod, an orally administered small molecule that inhibits p38 mitogen-activated protein kinase alpha [3] - Neflamapimod aims to address synaptic dysfunction associated with neurodegenerative diseases, including Dementia with Lewy Bodies (DLB) [3] - A recent Phase 2b trial of neflamapimod was completed, focusing on patients with DLB [3]